CHJ.60019
Dextran
--
--
Ordering
Available Variants100 mg
CHJ.60019-100mg
Price
€221.60
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
100 mg | CHJ.60019-100mg | €221.60 |
analytical standard, 150,000
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Linear Formula | [C6H10O5]n |
|---|---|
| CAS Number | 9004-54-0 |
| NACRES | NA.24 |
| UNSPSC Code | 12352201 |
| EC Number | 232-677-5 |
| MDL number | MFCD00130935 |
Safety Information Handling visibility
| Storage Class | 11 - Combustible Solids |
|---|---|
| ppe | Eyeshields, Gloves, type N95 (US) |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
Technical Overview & Applications Use-case context
Dextran, with a CAS number of 9004-54-0, is a complex branched glucan composed of chains of varying lengths. It is a polysaccharide made up of a large number of glucose molecules bonded together, primarily through alpha-1,6-glycosidic linkages. Dextran is produced from the fermentation of sucrose by certain bacteria, such as Leuconostoc mesenteroides, and is commonly used in various biomedical and pharmaceutical applications. Its properties, including its solubility, viscosity, and molecular weight, can be tailored to suit specific requirements. Dextran is used as a plasma volume expander, in blood typing, and as a component of certain drug delivery systems, among other uses. Its biocompatibility and non-toxic nature make it a valuable material in medical research and clinical settings, where its unique properties can be leveraged to improve patient outcomes.
